Lawrence A. Reiter

Pfizer (United States)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Christopher S. Jones

National Kidney Foundation

Michael J. Munchhof

Epizyme (United States)

William H. Brissette

Pfizer (United States)

Peter G. Mitchell

University of Melbourne

Sung Jin Huh

Pennsylvania State University

Michail Shipitsin

AMAG Pharmaceuticals (United States)

Donald E. Chickering

AMAG Pharmaceuticals (United States)

Lori Lopresti‐Morrow

Pfizer (United States)

Gary J. Martinelli

Pfizer (United States)

Farrukh Vohidov

Massachusetts Institute of Technology

Cooperative Institutions

Pfizer (United States)

156

Harvard University

Yale University

AMAG Pharmaceuticals (United States)

Massachusetts Institute of Technology

Epizyme (United States)

Stanford University

Pfizer (United Kingdom)

University of Melbourne

Brigham and Women's Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs

PMC (2018)

Matthew R. Golder Jenny Liu Jannik N. Andersen Michail Shipitsin Farrukh Vohidov

Telmisartan

Active metabolite

Source

Cite

Citations (0)

Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket

Bioorganic & Medicinal Chemistry Letters (1999)

Lawrence A. Reiter James P. Rizzi Jayvardhan Pandit Michael J. Lasut Shunda M. McGahee

Phosphinate

IC50

Binding pocket

10.1016/s0960-894x(98)00729-x

Cite

Citations (34)

ChemInform Abstract: Synthesis of 4(5)‐Acyl‐, 1‐Substituted 5‐Acyl‐, and 1‐Substituted 4‐Acyl‐1H‐imidazoles from 4‐Aminoisoxazoles.

ChemInform (1988)

Lawrence A. Reiter

Abstract The 4‐aminoisoxazoles (I), which are prepared by reduction of the corresponding nitro compounds, are acylated to yield the amides (III).

Acyl group

Nucleophilic acyl substitution

10.1002/chin.198801211

Cite

Citations (0)

Correction to Discovery of the Hemifumarate and (α-l-Alanyloxy)methyl Ether as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH Group

Journal of Medicinal Chemistry (2018)

Ralph P. Robinson Lawrence A. Reiter Wayne E. Barth Anthony M. Campeta Kelvin Cooper

ADVERTISEMENT RETURN TO ISSUEPREVAddition/CorrectionNEXTORIGINAL ARTICLEThis notice is a correctionCorrection to Discovery of the Hemifumarate and (α-l-Alanyloxy)methyl Ether as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH GroupRalph P. Robinson*Ralph P. RobinsonMore by Ralph P. Robinsonhttp://orcid.org/0000-0002-4066-5299, Lawrence A. ReiterLawrence A. ReiterMore by Lawrence A. Reiter, Wayne E. BarthWayne E. BarthMore by Wayne E. Barth, Anthony M. CampetaAnthony M. CampetaMore by Anthony M. Campeta, Kelvin CooperKelvin CooperMore by Kelvin Cooper, Brian J. CroninBrian J. CroninMore by Brian J. Cronin, Rosalina DestitoRosalina DestitoMore by Rosalina Destito, Kathleen M. DonahueKathleen M. DonahueMore by Kathleen M. Donahue, Fred C. FalknerFred C. FalknerMore by Fred C. Falkner, Eugene F. FieseEugene F. FieseMore by Eugene F. Fiese, Diane L. JohnsonDiane L. JohnsonMore by Diane L. Johnson, Alexander V. KupermanAlexander V. KupermanMore by Alexander V. Kuperman, Theodore E. ListonTheodore E. ListonMore by Theodore E. Liston, Deborah MalloyDeborah MalloyMore by Deborah Malloy, John J. MartinJohn J. MartinMore by John J. Martin, David Y. MitchellDavid Y. MitchellMore by David Y. Mitchell, Frank W. RusekFrank W. RusekMore by Frank W. Rusek, Sheri L. ShamblinSheri L. ShamblinMore by Sheri L. Shamblin, and Charles F. WrightCharles F. WrightMore by Charles F. WrightCite this: J. Med. Chem. 2018, 61, 7, 3237Publication Date (Web):March 28, 2018Publication History Published online28 March 2018Published inissue 12 April 2018https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00306https://doi.org/10.1021/acs.jmedchem.8b00306correctionACS PublicationsCopyright © 2018 American Chemical Society. This publication is available under these Terms of Use. Request reuse permissions This publication is free to access through this site. Learn MoreArticle Views848Altmetric-Citations1LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail PDF (188 KB) Get e-Alertsclose Get e-Alerts

10.1021/acs.jmedchem.8b00306

Cite

Citations (52)

Difluoroketones as inhibitors of matrix metalloprotease-13

Bioorganic & Medicinal Chemistry Letters (2000)

Lawrence A. Reiter Gary J. Martinelli Lisa A Reeves Peter G. Mitchell

Matrix metalloproteinase inhibitor

10.1016/s0960-894x(00)00287-0

Cite

Citations (29)

Inhibition of Interleukin‐1—Stimulated Collagen Degradation in Cartilage Explants

Annals of the New York Academy of Sciences (1994)

Peter G. Mitchell Lori Lopresti‐Morrow Sue A. Yocum Francis J. Sweeney Lawrence A. Reiter

10.1111/j.1749-6632.1994.tb24764.x

Cite

Citations (3)

Peptidic p‐nitroanilide substrates of interleukin‐1β‐converting enzyme

International journal of peptide & protein research (1994)

Lawrence A. Reiter

Peptidic p-nitroanilides are useful colorimetric substrates for enzymes. With the aim of developing a convenient, quantitative assay for inhibitors of interleukin-1 beta-converting enzyme (ICE), we have explored three approaches to the synthesis of peptidic p-nitroanilides relevant to this enzyme. The first approach involved a late stage oxidation of a p-aminoanilide such as CbzValAlaAsp(beta- tert-butyl)-p-(t-Boc-amino)anilide. The second and third approaches used the preformed amino acid p-nitroanilides HAsp-p-nitroanilide hydrochloride and HAsp(beta-tert-butyl)-p-nitroanilide which were coupled iteratively with preactivated amino acid derivatives or with an appropriate peptide, respectively. While each approach had it merits and limitations, all three produced p-nitroanilides that were substrates for ICE.

Hydrochloride

10.1111/j.1399-3011.1994.tb00379.x

Cite

Citations (15)

The identification of orally bioavailable thrombopoietin agonists

Bioorganic & Medicinal Chemistry Letters (2009)

Michael J. Munchhof Amy S. Antipas Laura C. Blumberg William H. Brissette Matthew F. Brown

Benzamide

Moiety

10.1016/j.bmcl.2009.01.032

Cite

Citations (5)

Potent, selective pyrimidinetrione-based inhibitors of MMP-13

Bioorganic & Medicinal Chemistry Letters (2006)

Lawrence A. Reiter Kevin D. Freeman‐Cook Christopher S. Jones Gary J. Martinelli Amy S. Antipas

Polar surface area

Molecular model

IC50

10.1016/j.bmcl.2006.08.066

Cite

Citations (47)

ChemInform Abstract: PTERIDINES. 50. UNEQUIVOCAL TOTAL SYNTHESIS OF DEOXYUROTHIONE

Chemischer Informationsdienst (1982)

E. D. TAYLOR Lawrence A. Reiter

Abstract Aus dem Pyrazin‐N‐oxid‐aldoxim (I) oder aus dem Pyrazin‐dinitril (III) ist mit Phosphoroxy‐ Chlorid das geschützte Chlor‐nitril (II) zugänglich, das zu (IVa) und (IVb) substitu‐ iert und weiter zu (V) cyclokondensiert wird.

10.1002/chin.198232241

Cite

Citations (2)